Observational Study to Evaluate Risks of Side Effects, Drug Abuse and Dependence in Patients Who Received Xyrem ® on Prescription

Recruiting

You are on the General Public view

  • Source

    -
    Public Title Observational Study to Evaluate Risks of Side Effects, Drug Abuse and Dependence in Patients Who Received Xyrem ® on Prescription
    Acronym Sorry, not currently available
    Source of Record URL http://clinicaltrials.gov/show/NCT00244465

  • Trial

    -
    Health Condition(s) or Problem Narcolepsy
    Lay Summary Patients will be followed up for max 18 months. Information on the Adverse Events and potential misuse or abuse of Xyrem ® will be collected. (from ClinicalTrials.gov)
    Who can enter the trial Inclusion Criteria: - Patients who received Xyrem ® on prescription Exclusion Criteria: - No limitations
    Who cannot enter the trial Inclusion Criteria: - Patients who received Xyrem ® on prescription Exclusion Criteria: - No limitations
    What will happen Sorry, not currently available
    Primary aim Evaluation of risk for development adverse events, withdrawal syndrome and potential for dependence, abuse, overdose and misuse of Xyrem®. Obtaining information about adherence to Xyrem® prescribing information regarding indication and dosage.
    Secondary Aim Sorry, not currently available
    Participant Information Sheet Sorry, not currently available
    Website Sorry, not currently available
    Recruitment Status Recruiting
    Nation England
    Location Cambridge, Essex , Leicester

  • Contact

    -
    Contact for Public Queries UCB Clinical Trial Call Center Study Director +1 877 822 9493 (UCB)
    Contact for Scientific Queries Sorry, not currently available
Please note:
  1. The UKCTG information is designed to inform you of existing trials. If you wish to join a specific trial, you must discuss this with your own doctor who may decide to get in touch with the contact listed.
  2. The UKCTG is not responsible for the quality of the data displayed in the Gateway but can contact the data providers. Please contact us if you have any query regarding the quality of trial records.